SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wolmark N,Wang J,Mamounas E,Bryant J,Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monographs. 2001; 30: 96102.
  • 2
    Smith IC,Heys SD,Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 14561466.
  • 3
    Kuroi K,Toi M,Tsuda H,Kurosumi M,Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother. 2005; 59( suppl 2): S387S392.
  • 4
    Chaturvedi S,McLaren C,Schofield AC, et al. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast? Breast Cancer Res Treat. 2005; 93: 151158.
  • 5
    Ogston KN,Miller ID,Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12: 320327.
  • 6
    Cleator S,Parton M,Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer. 2002; 9: 183195.
  • 7
    Machiavelli MR,Romero AO,Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am. 1998; 4: 125131.
  • 8
    Honkoop AH,van Diest PJ,de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998; 77: 621626.
  • 9
    Warner E,Plewes DB,Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292: 13171325. Comments in:JAMA.2004;292:1368–1370;JAMA.2005;293:931; author reply, 931.
  • 10
    Kriege M,Brekelmans CT,Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427437.
  • 11
    Leach MO,Boggis CR,Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365: 17691778. Erratum in:Lancet.2005;365:1848. Comments in:Lancet.2005;366:291–292.Lancet.2005;365: 1747–1749.
  • 12
    Schelfout K,Van Goethem M,Kersschot E, et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol. 2004; 30: 501507.
  • 13
    Zhang Y,Fukatsu H,Naganawa S, et al. The role of contrast-enhanced MR mammography for determining candidates for breast conservation surgery. Breast Cancer. 2002; 9: 231239.
  • 14
    Rieber A,Schirrmeister H,Gabelmann A, et al. Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol. 2002; 75: 789798.
  • 15
    Liberman L,Morris EA,Dershaw DD,Abramson AF,Tan LK. MR. imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol. 2003; 180: 901910.
  • 16
    Abraham DC,Jones RC,Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996; 78: 91100.
  • 17
    Balu-Maestro C,Chapellier C,Bleuse A,Chanalet I,Chauvel C,Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment: benefits of MRI. Breast Cancer Res Treat. 2002; 72: 145152.
  • 18
    Weatherall PT,Evans GF,Metzger GJ,Saborrian MH,Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging. 2001; 13: 868875.
  • 19
    Gilles R,Guinebretiere JM,Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology. 1994; 191: 633638.
  • 20
    Trecate G,Ceglia E,Stabile F, et al. Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic imaging and pathologic evaluation of residual disease. Tumori. 1999; 85: 220228.
  • 21
    Rieber A,Brambs HJ,Gabelmann A,Heilmann V,Kreienberg R,Kuhn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002; 12: 17111719.
  • 22
    Martincich L,Montemurro F,De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004; 83: 6776.
  • 23
    Mehta RS,Schubbert T,Hsiang D, et al. High pathological complete remission rate following neoadjuvant taxane, carboplatin and trastuzumab therapy after doxorubicin and cyclophosphamide in Her-2 positive breast cancer patients [abstract]. Breast Cancer Res Treat. 2004; 88( suppl 1). Abstract 1110.
  • 24
    Ferretti G,Felici A,Papaldo P,Fabi A,Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007; 19: 5662.
  • 25
    Jones RL,Lakhani SR,Ring AE,Ashley S,Walsh G,Smith IE. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer. 2006; 94: 358362.
  • 26
    Ring AE,Smith IE,Ashley S,Fulford LG,Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004; 91: 20122017.
  • 27
    Vincent-Salomon A,Rousseau A,Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer. 2004; 40: 15021508.
  • 28
    Faneyte IF,Schrama JG,Peterse JL,Remijnse PL,Rodenhuis S,van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003; 88: 406412.
  • 29
    Colleoni M,Viale G,Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004; 10: 66226628.
  • 30
    Petit T,Wilt M,Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004; 40: 205211.
  • 31
    Prisack HB,Karreman C,Modlich O, et al. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-) chemotherapy. Anticancer Res. 2005; 25: 46154621.
  • 32
    Buzdar AU,Ibrahim NK,Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 36763685.
  • 33
    Pegram M,Hsu S,Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 18: 22412251.
  • 34
    Shih T,Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006; 28: 17791802.
  • 35
    Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006; 33(5 suppl 10 ): S1S7.
  • 36
    Martincich L,Montemurro F,Cirillo S, et al. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiol Med (Torino). 2003; 106: 5158.
  • 37
    Warren RM,Bobrow LG,Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004; 90: 13491360.
  • 38
    Yeh E,Slanetz P,Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005; 184: 868877.
  • 39
    Rosen EL,Blackwell KL,Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol. 2003; 181: 12751282.
  • 40
    Belli P,Costantini M,Malaspina C,Magistrelli A,Latorre G,Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006; 61: 946953.
  • 41
    Akazawa K,Tamaki Y,Taguchi T, et al. Preoperative evaluation of residual tumor extent by 3-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006; 12: 130137.
  • 42
    Abrial SC,Penault-Llorca F,Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005; 94: 255263. Erratum in:Breast Cancer Res Treat.2006;98:365. Amat, Catherine [removed]; Abrial, Catherine [corrected to Abrial, Sophie Catherine].
  • 43
    Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer—recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer. 2004; 11: 139147.